{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T23:33:58Z","timestamp":1781220838969,"version":"3.54.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,21]],"date-time":"2022-11-21T00:00:00Z","timestamp":1668988800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,21]],"date-time":"2022-11-21T00:00:00Z","timestamp":1668988800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Endocr Disord"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background and objectives<\/jats:title>\n                <jats:p>Polycystic ovary syndrome (PCOS) is a common endocrine disorder with heterogeneous aetiology. It is characterized by irregular menses and or oligo\/anovulation, hyper-androgenism, and polycystic ovaries. The prevalence and diagnosis of PCOS changes depending on which clinical criteria are utilized to confirm the diagnosis. The prevalence can be high as 8\u201313% when the Rotterdam criteria are used. However, there is significant inter-individual variation in presentation. We have studied the socio-demographic and clinical characteristics of PCOS patients attending the Endocrinology clinic in a tertiary care institute in Sri Lanka.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A descriptive cross sectional study was conducted from September 2019 to September 2020 at the Endocrinology Unit of the National Hospital of Sri Lanka. All the patients who met the inclusion and exclusion criteria and who has a diagnosis of PCOS made according to Rotterdam criteria were recruited in to the study. After obtaining informed written consent, the data was collected using an interviewer administered questionnaire. HOMA-IR was calculated using the fasting insulin and blood glucose level.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The study enrolled sixty females. The mean age was 26.7\u00a0years (range 18\u201344). The mean weight was 64.8 (SD\u2009=\u200911.9) kg and BMI was 27.1 (SD\u2009=\u20094.8) kg\/m<jats:sup>\u22122<\/jats:sup>. According to Asian BMI cut-offs, 1 (1.7%) patient was underweight and 13 (21.7%) had normal weight. Forty six (76.7%) had their weight in the overweight or obese category. Fifty four (90.0%) patients had clinical or biochemical evidence of hyperandrogenism while 24 (40%) had polycystic ovaries on trans-abdominal ultrasound scan and 50 (83.3%) had irregular menstrual cycles. According to the body fat percentage assessed by the whole body DEXA scan 4.1% normal body fat, while 50.0% and 45.8% had overweight and obesity respectively. HOMA-IR detected 61.1% to have high insulin resistance. Out of the patients who had USS of the abdomen 27.5% had co-existent non-alcoholic fatty liver. Fifty four percent of the patients had sub\/infertility.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The majority of the population were overweight or obese and had higher prevalence of insulin resistance and non-alcoholic fatty liver. Out of the clinical characteristics used to make the diagnosis of PCOS, the presence of clinical or biochemical evidence of hyperandrogenism and irregular menstrual cycles are more common than the detection of polycystic ovaries on trans-vaginal USS. The higher prevalence of overweight, obesity, insulin resistance and NAFLD associated with PCOS makes the diagnosis and management of the disease crucial to prevent long term consequences of the disease.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12902-022-01206-0","type":"journal-article","created":{"date-parts":[[2022,11,21]],"date-time":"2022-11-21T10:03:04Z","timestamp":1669024984000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Evaluation of socio-demographic and clinical characteristics of PCOS patients attending a tertiary care institute in Colombo"],"prefix":"10.1186","volume":"22","author":[{"given":"I.","family":"Ranathunga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. G.","family":"Athukorala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. R.","family":"Sumanatilleke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. P.","family":"Somasundaram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,21]]},"reference":[{"issue":"12","key":"1206_CR1","doi-asserted-by":"publisher","first-page":"2841","DOI":"10.1093\/humrep\/dew218","volume":"31","author":"G Bozdag","year":"2016","unstructured":"Bozdag G, Mumusoglu S, Zengin D, Karabulut E, Yildiz BO. The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod. 2016;31(12):2841\u201355.","journal-title":"Hum Reprod"},{"issue":"6","key":"1206_CR2","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1210\/jc.2003-032046","volume":"89","author":"R Azziz","year":"2004","unstructured":"Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab. 2004;89(6):2745\u20139.","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"1206_CR3","first-page":"2434","volume":"85","author":"M Asunci\u00f3n","year":"2000","unstructured":"Asunci\u00f3n M, Calvo RM, San Mill\u00e1n JL, Sancho J, Avila S, Escobar-Morreale HF. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab. 2000;85(7):2434\u20138.","journal-title":"J Clin Endocrinol Metab"},{"key":"1206_CR4","first-page":"4","volume-title":"Polycystic Ovary Syndrome","author":"C Farquhar","year":"2007","unstructured":"Farquhar C. Introduction and history of polycystic ovary syndrome. In: Kovacs G, Norman R, editors. Polycystic Ovary Syndrome. 2nd ed. Cambridge, UK: Cambridge University Press; 2007. p. 4\u201324.","edition":"2"},{"issue":"8","key":"1206_CR5","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1093\/oxfordjournals.humrep.a136243","volume":"10","author":"AH Balen","year":"1995","unstructured":"Balen AH, Conway GS, Kaltsas G, Techatrasak K, Manning PJ, West C, et al. Polycystic ovary syndrome: the spectrum of the disorder in 1741 patients. Hum Reprod. 1995;10(8):2107\u201311.","journal-title":"Hum Reprod"},{"issue":"5","key":"1206_CR6","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.bpobgyn.2004.05.001","volume":"18","author":"R Hart","year":"2004","unstructured":"Hart R, Hickey M, Franks S. Definitions, prevalence and symptoms of polycystic ovaries and polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol. 2004;18(5):671\u201383.","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"issue":"2","key":"1206_CR7","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1210\/jc.2003-031122","volume":"89","author":"R Azziz","year":"2004","unstructured":"Azziz R, Sanchez LA, Knochenhauer ES, Moran C, Lazenby J, Stephens KC, et al. Androgen excess in women: experience with over 1000 consecutive patients. J Clin Endocrinol Metab. 2004;89(2):453\u201362.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"1206_CR8","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.fertnstert.2011.09.024","volume":"97","author":"BCJM Fauser","year":"2012","unstructured":"Fauser BCJM, Tarlatzis BC, Rebar RW, Legro RS, Balen AH, Lobo R, et al. Consensus on women\u2019s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE\/ASRM-Sponsored 3rd PCOS consensus workshop group. Fertil Steril. 2012;97(1):28-38.e25.","journal-title":"Fertil Steril"},{"key":"1206_CR9","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1210\/jcem-21-11-1440","volume":"21","author":"D Ferriman","year":"1961","unstructured":"Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab. 1961;21:1440\u20137.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6543","key":"1206_CR10","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1136\/bmj.293.6543.355","volume":"293","author":"J Adams","year":"1986","unstructured":"Adams J, Polson DW, Franks S. Prevalence of polycystic ovaries in women with anovulation and idiopathic hirsutism. Br Med J (Clin Res Ed). 1986;293(6543):355\u20139.\u00a0Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/3089520.","journal-title":"Br Med J (Clin Res Ed)"},{"issue":"6","key":"1206_CR11","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1016\/j.ajog.2004.06.064","volume":"191","author":"I Souter","year":"2004","unstructured":"Souter I, Sanchez LA, Perez M, Bartolucci AA, Azziz R. The prevalence of androgen excess among patients with minimal unwanted hair growth. Am J Obstet Gynecol. 2004;191(6):1914\u201320.","journal-title":"Am J Obstet Gynecol"},{"issue":"3","key":"1206_CR12","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1046\/j.1365-2265.2002.01603.x","volume":"57","author":"CN Wijeyaratne","year":"2002","unstructured":"Wijeyaratne CN, Balen AH, Barth JH, Belchetz PE. Clinical manifestations and insulin resistance (IR) in polycystic ovary syndrome (PCOS) among South Asians and Caucasians: is there a difference? Clin Endocrinol (Oxf). 2002;57(3):343\u201350.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"10","key":"1206_CR13","doi-asserted-by":"publisher","first-page":"677","DOI":"10.5694\/j.1326-5377.1991.tb93959.x","volume":"155","author":"JA Eden","year":"1991","unstructured":"Eden JA. The polycystic ovary syndrome presenting as resistant acne successfully treated with cyproterone acetate. Med J Aust. 1991;155(10):677\u201380.","journal-title":"Med J Aust"},{"issue":"1","key":"1206_CR14","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/1741-7015-8-41","volume":"8","author":"H Teede","year":"2010","unstructured":"Teede H, Deeks A, Moran L. Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Med. 2010;8(1):41. https:\/\/doi.org\/10.1186\/1741-7015-8-41.","journal-title":"BMC Med"},{"issue":"1\u20132","key":"1206_CR15","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.mce.2012.07.011","volume":"373","author":"RJ Chang","year":"2013","unstructured":"Chang RJ, Cook-Andersen H. Disordered follicle development. Mol Cell Endocrinol. 2013;373(1\u20132):51\u201360.","journal-title":"Mol Cell Endocrinol"},{"issue":"1","key":"1206_CR16","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/S0015-0282(00)01666-6","volume":"75","author":"CJ Glueck","year":"2001","unstructured":"Glueck CJ, Phillips H, Cameron D, Sieve-Smith L, Wang P. Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: a pilot study. Fertil Steril. 2001;75(1):46\u201352.","journal-title":"Fertil Steril"},{"key":"1206_CR17","first-page":"377","volume-title":"The Polycystic Ovary Syndrome","author":"JK DA Zawadski","year":"1992","unstructured":"DA Zawadski JK. Diagnostic criteria for polycystic ovary syndrome. In: Givens JHF, Merriman G, editors. The Polycystic Ovary Syndrome. Cambridge, MA: Blackwell Scientific; 1992. p. 377\u201384."},{"key":"1206_CR18","doi-asserted-by":"publisher","unstructured":"Rotterdam ESHRE\/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003\u00a0consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81(1):19\u201325. https:\/\/doi.org\/10.1016\/j.fertnstert.2003.10.004.","DOI":"10.1016\/j.fertnstert.2003.10.004"},{"issue":"11","key":"1206_CR19","doi-asserted-by":"publisher","first-page":"4237","DOI":"10.1210\/jc.2006-0178","volume":"91","author":"R Azziz","year":"2006","unstructured":"Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, et al. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an androgen excess society guideline. J Clin Endocrinol Metab. 2006;91(11):4237\u201345.","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"1206_CR20","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1093\/humrep\/12.12.2641","volume":"12","author":"S Franks","year":"1997","unstructured":"Franks S, Gharani N, Waterworth D, Batty S, White D, Williamson R, et al. The genetic basis of polycystic ovary syndrome. Hum Reprod. 1997;12(12):2641\u20138.","journal-title":"Hum Reprod"},{"issue":"5","key":"1206_CR21","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.bpobgyn.2004.05.002","volume":"18","author":"P Amato","year":"2004","unstructured":"Amato P, Simpson JL. The genetics of polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol. 2004;18(5):707\u201318.","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"issue":"6","key":"1206_CR22","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1210\/jc.2005-1494","volume":"91","author":"JM Vink","year":"2006","unstructured":"Vink JM, Sadrzadeh S, Lambalk CB, Boomsma DI. Heritability of polycystic ovary syndrome in a Dutch twin-family study. J Clin Endocrinol Metab. 2006;91(6):2100\u20134.","journal-title":"J Clin Endocrinol Metab"},{"key":"1206_CR23","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.metabol.2003.10.005","volume":"53","author":"M Salehi","year":"2004","unstructured":"Salehi M, Bravo-Vera R, Sheikh A, Gouller A, Poretsky L. Pathogenesis of polycystic ovary syndrome: what is the role of obesity? Metab Clin Exp. 2004;53:358\u201376.","journal-title":"Metab Clin Exp"},{"key":"1206_CR24","doi-asserted-by":"publisher","unstructured":"Moran LJ, Hutchison SK, Norman RJ, Teede HJ. Lifestyle changes in women with polycystic ovary syndrome. Cochrane database Syst Rev. 2011;(7):CD007506. https:\/\/doi.org\/10.1002\/14651858.cd007506.pub3.","DOI":"10.1002\/14651858.cd007506.pub3"},{"issue":"6","key":"1206_CR25","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.1210\/jc.2006-0108","volume":"91","author":"E Codner","year":"2006","unstructured":"Codner E, Soto N, Lopez P, Trejo L, Avila A, Eyzaguirre FC, et al. Diagnostic criteria for polycystic ovary syndrome and ovarian morphology in women with type 1 diabetes mellitus. J Clin Endocrinol Metab. 2006;91(6):2250\u20136.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"1206_CR26","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.2337\/diacare.24.6.1050","volume":"24","author":"HR Peppard","year":"2001","unstructured":"Peppard HR, Marfori J, Iuorno MJ, Nestler JE. Prevalence of polycystic ovary syndrome among premenopausal women with type 2 diabetes. Diabetes Care. 2001;24(6):1050\u20132.","journal-title":"Diabetes Care"},{"issue":"2","key":"1206_CR27","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.diabres.2007.12.022","volume":"80","author":"M Kashanian","year":"2008","unstructured":"Kashanian M, Fazy Z, Pirak A. Evaluation of the relationship between gestational diabetes and a history of polycystic ovarian syndrome. Diabetes Res Clin Pract. 2008;80(2):289\u201392.","journal-title":"Diabetes Res Clin Pract"},{"issue":"9","key":"1206_CR28","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.2337\/diab.38.9.1165","volume":"38","author":"A Dunaif","year":"1989","unstructured":"Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes. 1989;38(9):1165\u201374.","journal-title":"Diabetes"},{"issue":"6 Suppl 3","key":"1206_CR29","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.1212\/WNL.66.66_suppl_3.S23","volume":"66","author":"AG Herzog","year":"2006","unstructured":"Herzog AG. Menstrual disorders in women with epilepsy. Neurology. 2006;66(6 Suppl 3):S23\u20138.","journal-title":"Neurology"},{"issue":"3","key":"1206_CR30","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1210\/jc.2006-2012","volume":"92","author":"RL Rosenfield","year":"2007","unstructured":"Rosenfield RL. Clinical review: Identifying children at risk for polycystic ovary syndrome. J Clin Endocrinol Metab. 2007;92(3):787\u201396.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"1206_CR31","first-page":"935","volume":"28","author":"I Tsouma","year":"2014","unstructured":"Tsouma I, Kouskouni E, Demeridou S, Boutsikou M, Hassiakos D, Chasiakou A, et al. Lipid lipoprotein profile alterations in Greek infertile women with polycystic ovaries: influence of adipocytokines levels. In Vivo (Brooklyn). 2014;28(5):935\u20139.","journal-title":"In Vivo (Brooklyn)"},{"issue":"4","key":"1206_CR32","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1210\/jc.2005-2430","volume":"91","author":"JC Lo","year":"2006","unstructured":"Lo JC, Feigenbaum SL, Yang J, Pressman AR, Selby JV, Go AS. Epidemiology and adverse cardiovascular risk profile of diagnosed polycystic ovary syndrome. J Clin Endocrinol Metab. 2006;91(4):1357\u201363.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"1206_CR33","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1046\/j.1365-2265.2000.01000.x","volume":"52","author":"S Wild","year":"2000","unstructured":"Wild S, Pierpoint T, McKeigue P, Jacobs H. Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study. Clin Endocrinol (Oxf). 2000;52(5):595\u2013600.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"7","key":"1206_CR34","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1007\/BF00280883","volume":"28","author":"DR Matthews","year":"1985","unstructured":"Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412\u20139.","journal-title":"Diabetologia"},{"issue":"Suppl 1","key":"1206_CR35","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.2337\/dc17-S005","volume":"40","author":"American Diabetes Association","year":"2017","unstructured":"American Diabetes Association. Classification and diagnosis of diabetes. Diabetes Care. 2017;40(Suppl 1):S11-24.","journal-title":"Diabetes Care"},{"issue":"3","key":"1206_CR36","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1093\/ajcn\/72.3.694","volume":"72","author":"D Gallagher","year":"2000","unstructured":"Gallagher D, Heymsfield SB, Heo M, Jebb SA, Murgatroyd PR, Sakamoto Y. Healthy percentage body fat ranges: an approach for developing guidelines based on body mass index. Am J Clin Nutr. 2000;72(3):694\u2013701.","journal-title":"Am J Clin Nutr"},{"issue":"9403","key":"1206_CR37","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S0140-6736(03)15268-3","volume":"363","author":"WHO Expert Cotationnsul","year":"2004","unstructured":"WHO Expert Cotationnsul. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet (London, England). 2004;363(9403):157\u201363.","journal-title":"Lancet (London, England)"},{"issue":"10","key":"1206_CR38","doi-asserted-by":"publisher","first-page":"623","DOI":"10.29252\/ijrm.16.10.623","volume":"16","author":"A Hestiantoro","year":"2018","unstructured":"Hestiantoro A, Kapnosa Hasani RD, Shadrina A, Situmorang H, Ilma N, Muharam R, et al. Body fat percentage is a better marker than body mass index for determining inflammation status in polycystic ovary syndrome. Int J Reprod Biomed. 2018;16(10):623\u20138.","journal-title":"Int J Reprod Biomed"},{"issue":"6","key":"1206_CR39","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1111\/cen.13828","volume":"89","author":"EW Gilbert","year":"2018","unstructured":"Gilbert EW, Tay CT, Hiam DS, Teede HJ, Moran LJ. Comorbidities and complications of polycystic ovary syndrome: An overview of systematic reviews. Clin Endocrinol (Oxf). 2018;89(6):683\u201399. https:\/\/doi.org\/10.1111\/cen.13828.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"1206_CR40","doi-asserted-by":"publisher","first-page":"14","DOI":"10.5005\/jp-journals-10016-1165","volume":"9","author":"AAM Mangalath","year":"2018","unstructured":"Mangalath AAM, Alias A, Sajith M, Nimbargi V, Kumdale S. Sociodemographic characteristics and clinical presentation of infertile women with polycystic ovary syndrome in a tertiary care hospital. Int J Infertil Fetal Med. 2018;9(1):14\u20138.","journal-title":"Int J Infertil Fetal Med"}],"container-title":["BMC Endocrine Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-022-01206-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12902-022-01206-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-022-01206-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,22]],"date-time":"2022-11-22T15:06:35Z","timestamp":1669129595000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcendocrdisord.biomedcentral.com\/articles\/10.1186\/s12902-022-01206-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,21]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["1206"],"URL":"https:\/\/doi.org\/10.1186\/s12902-022-01206-0","relation":{},"ISSN":["1472-6823"],"issn-type":[{"value":"1472-6823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,21]]},"assertion":[{"value":"7 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was obtained from the Ethical Review committee of the National Hospital of Sri Lanka as well as the Ethics Review committee of the Post graduate institute of medicine, University of Colombo, Sri Lanka. All participants who enrolled in the study signed an informed consent form.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"None of the authors have any financial or non-financial competing interests to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"289"}}